PB2112: MINDWAY: A PHASE IB/II DOSE OPTIMIZATION STUDY TO ASSESS SAFETY AND PHARMACOKINETICS OF TAFASITAMAB + LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
oleh: R. Greil, K. Kopeckova, L. Arcaini, A. Amin, K. de Graaf, A.-M. Jegg
| Format: | Article |
|---|---|
| Diterbitkan: | Wiley 2022-06-01 |
Deskripsi
No description available for this item.